Works matching DE "ESOPHAGOGASTRIC junction cancer"


Results: 321
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36

    VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

    Published in:
    BMC Cancer, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1471-2407-14-476
    By:
    • Thomaidis, Thomas;
    • Maderer, Annett;
    • Al-Batran, Salah-Eddin;
    • Kany, Janis;
    • Pauligk, Claudia;
    • Steinmetz, Kristina;
    • Schad, Arno;
    • Hofheinz, Ralf;
    • Schmalenberg, Harald;
    • Homann, Nils;
    • Galle, Peter Robert;
    • Moehler, Markus
    Publication type:
    Article
    37

    Clinical validation of the EORTC QLQ-OG25 questionnaire for the evaluation of health-related quality of life in Mexican patients with esophagogastric cancers.

    Published in:
    Psycho-Oncology, 2012, v. 21, n. 7, p. 745, doi. 10.1002/pon.1974
    By:
    • Oñate‐Ocaña, Luis F.;
    • Velázquez‐Monroy, Natalia;
    • Vázquez, Luis;
    • Espinosa‐Mireles‐de‐Villafranca, Pablo;
    • Núñez‐Rosas, Elvia;
    • Ovando‐Lezama, Maira;
    • Vilar‐Compte, Diana;
    • García‐Hubard, Gabriela;
    • Carrillo, José F.;
    • Blazeby, Jane M.;
    • Aiello‐Crocifoglio, Vincenzo
    Publication type:
    Article
    38
    39
    40
    41
    42
    43

    Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 3, p. 1007, doi. 10.1007/s00432-022-03953-y
    By:
    • Stolze, T.;
    • Franke, S.;
    • Haybaeck, J.;
    • Moehler, M.;
    • Grimminger, P. P.;
    • Lang, H.;
    • Roth, W.;
    • Gockel, I.;
    • Kreuser, N.;
    • Bläker, H.;
    • Wittekind, C.;
    • Lordick, F.;
    • Vieth, M.;
    • Veits, L.;
    • Waidmann, O.;
    • Lingohr, P.;
    • Peitz, U.;
    • Schildberg, C.;
    • Kruschewski, M.;
    • Vassos, N.
    Publication type:
    Article
    44

    CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 3, p. 559, doi. 10.1007/s00432-017-2565-5
    By:
    • Schmalenberg, Harald;
    • Al-Batran, Salah-Eddin;
    • Pauligk, Claudia;
    • Zander, Thomas;
    • Reichart, Alexander;
    • Lindig, Udo;
    • Kleiß, Mathias;
    • Müller, Lothar;
    • Bolling, Claus;
    • Seufferlein, Thomas;
    • Reichardt, Peter;
    • Kullmann, Frank;
    • Eschenburg, Henning;
    • Schmittel, Alexander;
    • Egger, Matthias;
    • Block, Andreas;
    • Goetze, Thorsten Oliver
    Publication type:
    Article
    45

    Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2013, v. 139, n. 2, p. 337, doi. 10.1007/s00432-012-1335-7
    By:
    • Gencer, Deniz;
    • Al-Batran, Salah-Eddin;
    • Dada, Reyad;
    • Hünerlitürkoglu, Ali-Nuri;
    • Gonnermann, Michael;
    • Kegel, Thomas;
    • Scheiber, Harald;
    • Jordan, Wolf-Oliver;
    • Burkholder, Iris;
    • Kellermann, Lenka;
    • Hofheinz, Ralf-Dieter
    Publication type:
    Article
    46
    47
    48
    49

    Western strategy for EGJ carcinoma.

    Published in:
    Gastric Cancer, 2017, v. 20, p. 60, doi. 10.1007/s10120-016-0685-2
    By:
    • Giacopuzzi, Simone;
    • Bencivenga, Maria;
    • Weindelmayer, Jacopo;
    • Verlato, Giuseppe;
    • Manzoni, Giovanni
    Publication type:
    Article
    50

    Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.

    Published in:
    Gastric Cancer, 2017, v. 20, n. 2, p. 358, doi. 10.1007/s10120-016-0618-0
    By:
    • Moehler, Markus;
    • Weinmann, Arndt;
    • Mansoor, Wasat;
    • Mahlberg, Rolf;
    • Heinemann, Volker;
    • Obermannová, Radka;
    • Kubala, Eugen;
    • Melichar, Bohuslav;
    • Scigalla, Paul;
    • Tesařová, Marietta;
    • Janda, Petr;
    • Hédouin-Biville, Fabienne
    Publication type:
    Article